Ovid Therapeutics Inc (OVID) — Cash Flow-to-Debt Ratio
Ovid Therapeutics Inc (OVID) has a Cash Flow-to-Debt Ratio of -0.51x as of December 2025, meaning its operating cash flow of $-10.41 Million could theoretically repay -1% of its total liabilities ($20.27 Million) in one year. See Ovid Therapeutics Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ovid Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Ovid Therapeutics Inc across 12 annual periods. Also explore Ovid Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Ovid Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Ovid Therapeutics Inc. For market capitalisation and broader financial context, see Ovid Therapeutics Inc (OVID) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.89x | $-38.33 Million | $20.27 Million | ▲ +19.1% |
| 2024 | -2.34x | $-55.96 Million | $23.94 Million | ▼ -187.1% |
| 2023 | -0.81x | $-45.78 Million | $56.23 Million | ▲ +66.1% |
| 2022 | -2.40x | $-55.23 Million | $22.99 Million | ▼ -130.0% |
| 2021 | 8.02x | $118.61 Million | $14.80 Million | ▲ +601.8% |
| 2020 | -1.60x | $-51.58 Million | $32.29 Million | ▲ +66.2% |
| 2019 | -4.72x | $-51.09 Million | $10.82 Million | ▲ +8.3% |
| 2018 | -5.15x | $-45.56 Million | $8.84 Million | ▲ +1.4% |
| 2017 | -5.23x | $-31.47 Million | $6.02 Million | ▼ -9.6% |
| 2016 | -4.77x | $-17.80 Million | $3.73 Million | ▼ -100.7% |
| 2015 | -2.38x | $-5.49 Million | $2.31 Million | ▼ -9.1% |
| 2014 | -2.18x | $-261.28K | $119.95K | — |